Story perspectives

Summit Therapeutics Stock Plummets Amid Lung Cancer Drug Doubts

9/9/2025

Summary

Story summary

Summit Therapeutics' stock fell 25.2% after ivonescimab, its lung cancer drug, showed no significant overall survival benefits in trials.
While it demonstrated promise in progression-free survival, analysts question its FDA approval chances due to inconsistent subgroup data.
The drug is approved in China and holds Fast Track designation in the U.S.
Despite recent volatility, retail sentiment remains bullish, with shares up nearly 700% over five years.
Summit plans to finalize its U.S. approval strategy and conduct additional studies against Merck's Keytruda.

History

Historical Context

The FDA's approval of ipilimumab in 2011 marked a pivotal moment in cancer treatment, significantly improving melanoma survival rates by 20%. Summit Therapeutics, led by CEO Duggan since 2020, is currently facing challenges with ivonescimab, a drug under scrutiny for efficacy and safety, echoing past controversies in oncology that could impact future drug development and investor confidence.

1 of 2

Story summary

Summit Therapeutics' stock fell 25.2% after ivonescimab, its lung cancer drug, showed no significant overall survival benefits in trials.
While it demonstrated promise in progression-free survival, analysts question its FDA approval chances due to inconsistent subgroup data.
The drug is approved in China and holds Fast Track designation in the U.S.
Despite recent volatility, retail sentiment remains bullish, with shares up nearly 700% over five years.
Summit plans to finalize its U.S. approval strategy and conduct additional studies against Merck's Keytruda.

1 / 2